46 research outputs found

    Motivación de logro y rendimiento escolar en estudiantes del área de comunicación en educación primaria de la I. E. Nº 20825 “Túpac Amaru II” UGEL 15 Huarochirí, 2012

    Get PDF
    La presente investigación se plantea como objetivo establecerla relación entre “Motivación de logro y rendimiento escolar en estudiantes del área de Comunicación en Educación Primaria de la I. E. Nº 20825 “Túpac Amaru II” UGEL 15 - Huarochirí, 2012” El estudio no experimental que contó con la participación de125 estudiantes a quienes se les encuesto utilizando como instrumentos un cuestionario de escala para medir la motivación de logro y registro de notas en el área de comunicación para medir el rendimiento escolar. También se realizo el análisis psicométrico para el primer instrumento obteniendo su confiabilidad y valides satisfactoria. Los resultados de la investigación indican que 53,6% de la muestra se encuentran dentro de los niveles aceptables de motivación de logro, por otra parte el 27,2% se encuentran en niveles bajo, mientras que el 19,2% muestran un nivel relativamente alto. Respecto al rendimiento escolar el 60,8% de la muestra obtienen un rendimiento académico A, es decir logro esperado; y el 24,8% tienen un rendimiento académico destacado (AD), mientas que el 14,4% obtiene promedios en proceso (B). Así mismo los resultados demuestran que existe relación significativa entre la motivación de logro y el rendimiento escolar (r = 0.388; p<0.05). Finalmente este análisis nos permite concluir que cuanto más alto sea el nivel de la motivación de logro de los estudiantes mayor será el rendimiento escolar mostrado por los estudiantes

    Prodromal symptoms and the duration of untreated psychosis in first episode of psychosis patients: what differences are there between early vs. adult onset and between schizophrenia vs. bipolar disorder?

    Get PDF
    To assess the role of age (early onset psychosis-EOP &lt; 18 years vs. adult onset psychosis-AOP) and diagnosis (schizophrenia spectrum disorders-SSD vs. bipolar disorders-BD) on the duration of untreated psychosis (DUP) and prodromal symptoms in a sample of patients with a first episode of psychosis. 331 patients with a first episode of psychosis (7–35 years old) were recruited and 174 (52.6%) diagnosed with SSD or BD at one-year follow-up through a multicenter longitudinal study. The Symptom Onset in Schizophrenia (SOS) inventory, the Positive and Negative Syndrome Scale and the structured clinical interviews for DSM-IV diagnoses were administered. Generalized linear models compared the main effects and group interaction. 273 AOP (25.2 ± 5.1 years; 66.5% male) and 58 EOP patients (15.5 ± 1.8 years; 70.7% male) were included. EOP patients had significantly more prodromal symptoms with a higher frequency of trouble with thinking, avolition and hallucinations than AOP patients, and significantly different median DUP (91 [33–177] vs. 58 [21–140] days; Z = − 2.006, p = 0.045). This was also significantly longer in SSD vs. BD patients (90 [31–155] vs. 30 [7–66] days; Z = − 2.916, p = 0.004) who, moreover had different profiles of prodromal symptoms. When assessing the interaction between age at onset (EOP/AOP) and type of diagnosis (SSD/BD), avolition was significantly higher (Wald statistic = 3.945; p = 0.047), in AOP patients with SSD compared to AOP BD patients (p = 0.004). Awareness of differences in length of DUP and prodromal symptoms in EOP vs. AOP and SSD vs. BD patients could help improve the early detection of psychosis among minors

    La grabación sonora: un recurso pedagógico multidisciplinar para la reinterpretación de la Historia

    Get PDF
    Mediante el presente proyecto se ha pretendido abordar un nuevo acercamiento a la historia de la música, en tanto manifestación cultural, basado en una metodología de reciente creación que entronca directamente con los estudios sobre la praxis interpretativa. Para ello hemos profundizado en el correcto manejo de los software informáticos que permiten el análisis de estas fuentes sonoras (fundamentalmente visualizadores de ondas y editores de sonido). Como resultado, hemos constituido un grupo de trabajo abierto a profesores y alumnos, ubicado físicamente en la Facultad de Geografía e Historia de la UCM

    Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

    Get PDF
    Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio
    corecore